Anika Therapeutics Stock Forecast, Price & News

-1.07 (-2.61 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume334,986 shs
Average Volume131,242 shs
Market Capitalization$575.50 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Anika Therapeutics logo

About Anika Therapeutics

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.51 out of 5 stars

Medical Sector

568th out of 2,100 stocks

Surgical & Medical Instruments Industry

54th out of 174 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

Is Anika Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Anika Therapeutics stock.
View analyst ratings for Anika Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Anika Therapeutics?

Wall Street analysts have given Anika Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anika Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Anika Therapeutics

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, May, 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.19. The biotechnology company had revenue of $34.29 million for the quarter, compared to analysts' expectations of $32.39 million. Anika Therapeutics had a negative net margin of 20.83% and a negative trailing twelve-month return on equity of 0.98%.
View Anika Therapeutics' earnings history

How has Anika Therapeutics' stock been impacted by COVID-19?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANIK stock has increased by 9.9% and is now trading at $39.99.
View which stocks have been most impacted by COVID-19

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, June, 15th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.

What price target have analysts set for ANIK?

1 equities research analysts have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $43.00 to $43.00. On average, they anticipate Anika Therapeutics' share price to reach $43.00 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Anika Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Dr. Cheryl R. Blanchard, Pres, CEO & Director (Age 57, Pay $62.5k)
  • Mr. Thomas M. Finnerty, Exec. VP of HR (Age 63, Pay $550.34k)
  • Mr. James Loerop, Exec. VP of Bus. Devel. & Strategic Planning (Age 57, Pay $549.09k)
  • Mr. Michael L. Levitz, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Alexei Goraltchouk, Sr. VP of Operations & Project Management
  • Mr. Mark Namaroff, Exec. Director of Investor Relations & Corp. Communications (Age 58)
  • Mr. Charles Sherwood III, VP & Corp. Legal Counsel
  • Mr. David Colleran, Exec. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. James Chase, Sr. VP of International Sales & Marketing
  • Mr. Bart Bracy, VP of Sales & Marketing of Americas

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.42%), Kayne Anderson Rudnick Investment Management LLC (8.49%), Ameriprise Financial Inc. (6.93%), Dimensional Fund Advisors LP (5.98%), Renaissance Technologies LLC (5.18%) and Morgan Stanley (4.54%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, James Loerop, Jeffery S Thompson, Joseph L Bower, Raymond J Land and Sylvia Cheung.
View institutional ownership trends for Anika Therapeutics

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Los Angeles Capital Management LLC, Royal Bank of Canada, and Credit Suisse AG. Company insiders that have sold Anika Therapeutics company stock in the last year include James Loerop, and Raymond J Land.
View insider buying and selling activity for Anika Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Fort Washington Investment Advisors Inc. OH, BlackRock Inc., Millennium Management LLC, Capital Management Corp VA, Russell Investments Group Ltd., D. E. Shaw & Co. Inc., and Citigroup Inc..
View insider buying and selling activity for Anika Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $39.99.

How much money does Anika Therapeutics make?

Anika Therapeutics has a market capitalization of $575.50 million and generates $130.46 million in revenue each year. The biotechnology company earns $-23,980,000.00 in net income (profit) each year or $0.71 on an earnings per share basis.

How many employees does Anika Therapeutics have?

Anika Therapeutics employs 277 workers across the globe.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is

Where are Anika Therapeutics' headquarters?

Anika Therapeutics is headquartered at 32 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.